Last updated: October 6, 2026
Cyanokit is a niche emergency antidote based on hydroxocobalamin for suspected or confirmed cyanide poisoning. Its commercial economics differ from conventional pharmaceuticals: demand is driven by emergency preparedness, hospital formularies, emergency medical services, industrial exposure risk, and government procurement rather than chronic patient volume.
Cyanokit has a durable commercial position because rapid cyanide treatment has high clinical value, product substitution is operationally difficult, and purchasing decisions often prioritize readiness over unit price. Its limitations are equally clear: cyanide poisoning is rare, revenue is concentrated among institutional buyers, public financial disclosures do not isolate Cyanokit sales, and the core product has no meaningful remaining small-molecule exclusivity barrier.
What is Cyanokit and how is it used?
Cyanokit is an injectable hydroxocobalamin product used as an antidote for cyanide poisoning. The active ingredient binds cyanide to form cyanocobalamin, which is then excreted in the urine. The product is supplied as a sterile lyophilized powder that is reconstituted before intravenous administration.
The U.S. label identifies a 5-gram vial as the principal presentation. The recommended initial adult dose is 5 grams intravenously, with a second 5-gram dose available for severe poisoning or inadequate clinical response. Pediatric dosing is weight-based, subject to maximum dosing limits established in the label. [1]
What clinical events drive Cyanokit demand?
Cyanokit demand is associated with:
- Industrial fires and smoke inhalation
- Chemical manufacturing accidents
- Metal-processing and mining exposure
- Residential or commercial building fires
- Deliberate cyanide release or terrorism preparedness
- Sodium nitroprusside-associated cyanide toxicity
- Hospital emergency departments and poison-control protocols
- Stockpiling by governments, military agencies, and first responders
The product is often purchased before an exposure occurs. This creates an inventory and replacement market rather than a prescription-refill market.
When was Cyanokit approved by the FDA?
The FDA approved Cyanokit under NDA 022041 on December 15, 2006. The original U.S. applicant was Meridian Medical Technologies, Inc. [2]
| Milestone |
Date or status |
| Active ingredient |
Hydroxocobalamin |
| U.S. NDA |
022041 |
| Original FDA approval |
December 15, 2006 |
| Dosage form |
Intravenous lyophilized powder |
| Principal strength |
5 g per vial |
| FDA therapeutic category |
Cyanide antidote |
| Prescription status |
Prescription-only emergency medicine |
| Current U.S. commercial position |
Branded emergency antidote with institutional demand |
FDA approval was based on pharmacologic and clinical evidence appropriate for a cyanide antidote, including the product’s ability to bind cyanide and the difficulty of conducting conventional randomized efficacy trials in a rare, life-threatening poisoning setting.
What is the Orange Book status of Cyanokit?
Cyanokit’s commercial protection is primarily regulatory, operational, and market-based rather than patent-based. The FDA Orange Book should be reviewed for current listings because patent and exclusivity records can change, but Cyanokit does not have the profile of a recently launched small-molecule product protected by a large active patent estate.
How long does Cyanokit’s exclusivity last?
The original FDA approval occurred in 2006. Any standard new-drug exclusivity associated with that approval has expired. Pediatric exclusivity, if granted in connection with a later regulatory action, would also have expired by 2026.
The practical result is that a competing applicant can pursue an abbreviated or alternative regulatory pathway if it satisfies FDA requirements for hydroxocobalamin, intravenous formulation, manufacturing controls, and clinical labeling.
| Protection category |
Current commercial relevance |
| Original FDA exclusivity |
Expired |
| Pediatric exclusivity |
Expired if previously granted |
| Active core composition patent |
No material public exclusivity barrier identified |
| Formulation patents |
Limited commercial significance relative to regulatory and manufacturing controls |
| Method-of-use patents |
Not the principal barrier to competition |
| Trade secrets and know-how |
Potentially relevant to sterile manufacturing, stability, and supply reliability |
| Trademark |
Cyanokit brand remains commercially relevant even without core drug exclusivity |
What patents protect Cyanokit?
The principal active ingredient, hydroxocobalamin, is an established chemical entity. Cyanokit’s historical commercial protection did not depend on a new molecular entity patent comparable to those used for specialty medicines launched with 20-year composition-of-matter terms.
Potentially relevant intellectual-property categories include:
- Formulation and lyophilization processes.
- Reconstitution and packaging systems.
- Manufacturing processes for high-purity hydroxocobalamin.
- Product-specific stability data and container-closure systems.
- Trademark rights covering the Cyanokit name.
- Regulatory and commercial know-how relating to emergency deployment.
These rights do not create the same exclusionary effect as an unexpired composition patent. A generic or alternative hydroxocobalamin product could potentially compete if it demonstrates pharmaceutical equivalence, product quality, sterility, stability, and appropriate labeling.
What formulations are protected by Cyanokit?
The product’s most important technical characteristics are:
- High-dose intravenous hydroxocobalamin
- Lyophilized powder for reconstitution
- Large-volume emergency-use vial
- Sterile manufacturing
- Extended storage and transport requirements
- Packaging designed for rapid emergency preparation
The formulation is commercially important because a replacement product must match not only the active ingredient but also dose, sterility, reconstitution performance, stability, container closure, and emergency-use handling.
How strong is the Cyanokit patent estate?
Cyanokit has a weak-to-moderate patent estate but a stronger commercial franchise than its patent position alone would suggest.
| Factor |
Assessment |
| Composition-of-matter protection |
Weak or expired |
| Regulatory exclusivity |
Expired |
| Brand recognition |
Moderate to strong in emergency medicine |
| Clinical familiarity |
Strong |
| Manufacturing complexity |
Moderate to high |
| Hospital switching barriers |
Moderate |
| Government procurement advantage |
Potentially strong |
| Generic substitution risk |
Moderate |
| Immediate commoditization risk |
Low to moderate |
The product’s defensibility comes from availability, clinical familiarity, established emergency protocols, supplier qualification, and the consequences of a stockout. A hospital or government buyer may prefer a proven product even when a lower-cost alternative becomes available.
Which companies compete with Cyanokit?
Cyanokit competes with both hydroxocobalamin alternatives and older cyanide-antidote regimens.
Direct and indirect competitors
| Competitor |
Active ingredients or approach |
Competitive position |
| Generic hydroxocobalamin |
Hydroxocobalamin |
Direct substitute if approved and available |
| Nithiodote |
Sodium nitrite and sodium thiosulfate |
Established cyanide antidote alternative |
| Generic sodium thiosulfate |
Sodium thiosulfate |
Lower-cost component or alternative treatment |
| Sodium nitrite products |
Sodium nitrite |
Alternative antidote component |
| Amyl nitrite |
Inhaled nitrite |
Older, limited-use option |
| Supportive care |
Oxygen, airway management, seizure control, hemodynamic support |
Adjunctive, not a complete substitute |
Cyanokit has an important safety and usability advantage over nitrite-based therapy in patients with smoke inhalation or concurrent carbon monoxide exposure. Nitrites can induce methemoglobinemia, which may worsen tissue hypoxia when carbon monoxide exposure is present. This consideration supports hydroxocobalamin use in fire-related cyanide poisoning. [1]
How does Cyanokit compare with Nithiodote?
Cyanokit and Nithiodote occupy the same emergency-antidote category but have different clinical and commercial profiles.
| Attribute |
Cyanokit |
Nithiodote |
| Active therapy |
Hydroxocobalamin |
Sodium nitrite plus sodium thiosulfate |
| Principal risk |
Hypertension, chromaturia, laboratory interference |
Methemoglobinemia, hypotension, oxygen-delivery concerns |
| Fire and smoke inhalation use |
Often favored when cyanide and carbon monoxide exposure may coexist |
More constrained by methemoglobinemia risk |
| Dose preparation |
Reconstituted high-dose vial |
Combination antidote preparation |
| Patent position |
Mature and largely off-exclusivity |
Mature and largely off-exclusivity |
| Generic risk |
Moderate |
Moderate to high |
| Procurement economics |
Premium emergency-readiness product |
Lower-cost alternative in some settings |
Cyanokit generally commands a premium because of its perceived safety profile in smoke inhalation and its simplified clinical positioning. Nithiodote can retain demand where cost, existing protocols, or inventory availability dominate.
What is the market size for Cyanokit?
The addressable market is specialized and difficult to measure using conventional prescription-volume metrics. Demand consists of three components:
- Routine hospital and emergency-service inventory.
- Replacement of expired or deployed stock.
- Government and strategic preparedness procurement.
No reliable public source identifies global Cyanokit unit volume or standalone annual revenue. Manufacturer reporting aggregates Cyanokit within broader portfolios or does not disclose product-level sales.
A practical market model is driven by stocked locations rather than diagnosed patients:
| Demand driver |
Commercial effect |
| Number of hospitals stocking antidotes |
Determines baseline inventory |
| EMS and fire-service protocols |
Expands decentralized demand |
| Government preparedness programs |
Creates large but irregular orders |
| Product shelf life and expiry |
Generates recurring replacement demand |
| Industrial exposure risk |
Supports corporate and occupational-health purchases |
| Major fire or chemical event |
Produces episodic demand spikes |
| Generic availability |
Creates price pressure |
The product therefore has low epidemiologic volume but high value per prepared treatment course.
What is the financial trajectory of Cyanokit?
Cyanokit’s financial trajectory is best characterized as stable niche revenue with episodic procurement volatility, not as a high-growth prescription franchise.
The commercial pattern has four phases:
2006 to early commercialization
The product entered the U.S. market as a branded cyanide antidote with limited direct competition from equivalent hydroxocobalamin products. Early adoption depended on emergency departments, poison centers, fire services, and government preparedness programs.
Expansion of emergency preparedness demand
Cyanokit gained commercial support from its use in smoke inhalation and chemical-exposure protocols. Institutional buyers valued a product that could be deployed rapidly without the methemoglobinemia concerns associated with nitrites.
Portfolio ownership and distribution changes
Cyanokit has been associated with specialized pharmaceutical and rare-disease distribution structures rather than a mass-market primary-care sales force. Ownership and distribution arrangements have changed over time, including involvement by SERB and Recordati-related commercial operations in international and North American markets. [3][4]
Mature-market phase
The current phase is mature and replacement-driven. Revenue depends on:
- Contract renewals
- Government preparedness budgets
- Inventory rotation
- Hospital formulary retention
- Competitive product availability
- Pricing discipline
- Manufacturing continuity
There is no public, audited product-level revenue series sufficient to calculate a precise compound annual growth rate for Cyanokit. Recordati reports product and business-line information at an aggregated level, and Cyanokit is not separately reported as a major consolidated revenue category. [4]
What is Cyanokit’s revenue exposure for the manufacturer?
Cyanokit is commercially important as a specialized product, but it is unlikely to be a material driver of consolidated revenue for a large diversified pharmaceutical company.
Its financial value is stronger on a portfolio basis than on a total-company basis because it can provide:
- High revenue per treatment course
- Institutional customer relationships
- A differentiated emergency-medicine product
- Relatively low chronic-care marketing requirements
- Recurring stock-replacement purchases
- Strategic relevance in government preparedness
The main financial risks are concentration and volatility. A single government order can materially affect a small specialty company’s annual results, while the same order would be immaterial to a large diversified manufacturer.
What generic entry risks exist for Cyanokit?
Generic entry risk is real but gradual.
Primary generic risk factors
- Expired regulatory exclusivity
- Mature active ingredient
- Lack of a strong composition patent barrier
- Potential for hospital purchasing committees to mandate substitution
- Government pressure to reduce emergency-antidote costs
- Availability of established hydroxocobalamin manufacturing technology
Factors that limit rapid substitution
- Sterile high-dose manufacturing requirements
- Need for reliable long-term stability
- Emergency inventory qualification
- Limited cyanide-antidote market size
- Low clinical event frequency
- Procurement preference for established suppliers
- Need to maintain supply during rare but high-consequence events
- Potential product-specific differences in reconstitution and packaging
The likely generic-entry scenario is gradual price competition rather than immediate displacement. A credible competitor would need dependable supply and institutional acceptance, not only FDA approval.
Are there Paragraph IV challenges to Cyanokit?
No prominent public Paragraph IV litigation has reshaped the Cyanokit market in the manner seen with high-revenue chronic medicines. The reason is economic: the product’s market is comparatively small, and the reward for challenging an established emergency antidote may not justify the development, litigation, and manufacturing costs.
A future abbreviated application could still create an abbreviated new drug application dispute if the applicant seeks approval while relying on an Orange Book-listed patent. The commercial significance would depend on the existence of an active listed patent and the challenger’s ability to secure reliable sterile production.
What patent litigation affects Cyanokit?
No major ongoing patent litigation is publicly associated with Cyanokit as of the latest broadly available public information. The absence of major litigation is consistent with the product’s mature regulatory status and limited patent-based exclusivity.
Commercial disputes are more likely to involve:
- Supply contracts
- Government purchasing
- Distribution rights
- Product liability
- Manufacturing quality
- Regulatory compliance
- Pricing and substitution
These disputes can affect availability without creating the formal exclusivity consequences associated with a Paragraph IV patent case.
What is the FDA regulatory status of Cyanokit?
Cyanokit remains an FDA-approved prescription cyanide antidote under NDA 022041. The product is marketed for known or suspected cyanide poisoning and remains part of the emergency-medicine treatment landscape. [1][2]
Regulatory risk is lower than clinical-development risk because the product has an established label and long commercial history. Key continuing obligations include:
- Current good manufacturing practice compliance
- Sterility assurance
- Batch consistency
- Stability monitoring
- Pharmacovigilance
- Accurate labeling
- Supply continuity
- Management of known laboratory-interference effects
Hydroxocobalamin can cause red discoloration of skin and urine and can interfere with certain laboratory tests and dialysis-machine readings. These effects are clinically relevant and must be incorporated into hospital protocols. [1]
What manufacturing and intellectual-property barriers protect Cyanokit?
The strongest barriers are operational rather than legal.
Manufacturing barriers
A competitor must produce a sterile, high-dose, stable injectable product at commercial scale. The product must retain quality during storage, transportation, and emergency deployment. Manufacturing failures can have disproportionate reputational and procurement consequences because buyers purchase readiness as much as they purchase medication.
Supply-chain barriers
A supplier must maintain:
- Specialized raw-material sourcing
- Lyophilization capacity
- Sterile filling
- Quality-control testing
- Inventory sufficient for emergency demand
- Distribution across hospitals and response agencies
- Expiry replacement programs
These requirements reduce the number of economically viable competitors even when patent protection is weak.
When does Cyanokit lose exclusivity?
Cyanokit’s core regulatory exclusivity was lost years ago. The original 2006 approval does not provide a current market-exclusivity barrier. The product’s remaining commercial protection comes from brand familiarity, procurement relationships, clinical protocols, manufacturing expertise, and supply reliability.
A new competitor could enter without waiting for a future patent cliff if it satisfies FDA requirements and establishes a commercially viable supply chain.
What generic launch scenarios are most likely?
Scenario 1: No credible generic launch
The branded product maintains a premium because the market is too small to attract sustained generic investment. This is the most favorable scenario for the incumbent.
Scenario 2: One approved generic with limited distribution
A generic enters but remains a secondary supplier. Hospitals use it selectively, while government and emergency-service customers retain the established product for continuity.
Scenario 3: Multiple hydroxocobalamin suppliers
Price competition increases, particularly in hospital purchasing and government tenders. The branded product retains share through reliability, but gross margins decline.
Scenario 4: Institutional protocol substitution
Large health systems or public agencies adopt a lower-cost alternative after validating quality and supply. This scenario could produce the largest impact on branded volume.
What licensing deals affect Cyanokit?
Cyanokit has operated through specialized commercial and distribution arrangements involving companies such as Meridian Medical Technologies, SERB, and Recordati-related entities. Public disclosures indicate portfolio and regional commercial relationships rather than a widely publicized royalty structure or transformative licensing transaction dedicated solely to Cyanokit. [3][4]
The commercial value of future licensing would depend on geography. Markets with government preparedness programs, industrial chemical exposure, and large hospital networks are more attractive than low-volume regions without centralized procurement.
How does Cyanokit compare with other emergency antidotes?
Cyanokit has a stronger premium-product position than older nitrite-based antidotes but a weaker formal exclusivity position than recently approved specialty medicines.
| Metric |
Cyanokit |
Older nitrite-based antidotes |
New specialty antidote |
| Clinical familiarity |
High |
High in legacy protocols |
Variable |
| Patent protection |
Limited |
Limited |
Potentially strong |
| Emergency-use value |
High |
High |
Depends on indication |
| Market volume |
Low |
Low |
Uncertain |
| Institutional switching cost |
Moderate |
Moderate |
Potentially high |
| Revenue predictability |
Moderate |
Low to moderate |
Uncertain |
| Generic exposure |
Moderate |
High |
Low initially |
Key Takeaways
- Cyanokit is a mature, niche emergency antidote based on hydroxocobalamin.
- FDA approval dates to December 15, 2006, under NDA 022041.
- Core regulatory exclusivity has expired, and the product does not have a major current composition-patent barrier.
- The product’s commercial defensibility comes from clinical familiarity, emergency readiness, sterile manufacturing, supply reliability, and procurement relationships.
- Demand is driven by hospitals, EMS, fire services, industrial buyers, and government preparedness programs.
- Cyanokit competes primarily with Nithiodote and generic nitrite/thiosulfate regimens.
- Generic entry risk is moderate, but market size and manufacturing requirements limit the number of viable entrants.
- No major public Paragraph IV or patent litigation has materially changed the product’s market position.
- Product-level revenue and margin data are not separately disclosed in public company reporting.
- The financial trajectory is likely mature and replacement-driven, with episodic government and institutional procurement effects.
FAQs About Cyanokit Market and Exclusivity
Is Cyanokit still patent protected?
Cyanokit’s principal commercial protection is not based on an active composition patent. Brand, manufacturing, regulatory, and procurement advantages remain more important.
Can a generic hydroxocobalamin product compete with Cyanokit?
Yes. A generic applicant could potentially compete if it satisfies FDA requirements for product quality, sterility, stability, dosage, labeling, and manufacturing.
Does Cyanokit have an Orange Book patent?
Cyanokit does not have the profile of a product with a significant active Orange Book patent estate. Current Orange Book records remain the controlling source for any listed patent or exclusivity entry. [2]
Why does Cyanokit remain expensive if hydroxocobalamin is old?
The price reflects emergency inventory, high-dose sterile manufacturing, low market volume, expiry replacement, supply assurance, and institutional procurement economics.
Is Cyanokit revenue material to Recordati?
Public reporting does not separately quantify Cyanokit revenue. Relative to a diversified pharmaceutical company, the product is unlikely to be a major consolidated revenue driver, although it may be strategically important within a specialty emergency-medicine portfolio.
References
-
U.S. Food and Drug Administration. (2023). Cyanokit (hydroxocobalamin for injection) prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
SERB Pharmaceuticals. (2024). Cyanokit product information and company portfolio materials. SERB Pharmaceuticals.
-
Recordati S.p.A. (2024). Annual report and financial statements 2023. Recordati S.p.A.
